Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

as that remains blinded until April – resulted in Veru's stock declining almost 48% after the announcement. The fall came despite positive results on another secondary endpoint in QUALITY ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

About Veru Inc. Veru is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of cardiometabolic diseases, oncology, and ARDS. The Company’s drug ...

New and positive data for Maia Biotechnology Inc.’s lead candidate for a particularly deadly and advanced lung cancer propelled the stock modestly higher on Feb. 4. The pivotal phase II THIO-101 study ...

As the property security landscape evolves, Cloudastructure is strategically expanding its salesforce to address growing ...

Both Jefferies and Loop Capital downgraded Apple’s stock last week, with Jefferies analyst Edison Lee saying he expects Apple to report lower-than-anticipated results for the December quarter ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

These numbers suggest SpaceX is very profitable. If it can grow its revenue and profitability at high rates, it will give its stock the fuel to skyrocket in the future. Valuation is another ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...